Fig 1.
Clinical characteristics and EGFR mutation status rates categorised by smoking status and sex.
11 patients with unknown smoking status, and 6 who had samples indeterminate for EGFR mutational status were excluded. 464/762 (60.9%) tested positive for EGFR mutations (EGFR M+). The number of patients needed to test in order to pick up 1 EGFR mutant lung adenocarcinoma in any sub-population stratified by sex and smoking status, was less than 3 patients (male ES; 1/0.357 = 2.8).
Fig 2.
EGFR mutation rates amongst ever smokers classified by pack years.
Fig 3.
Sites of EGFR mutations amongst 461 patients.
Table 1.
Demographics of 211 patients treated with 1st line TKI.
Table 2.
Univariate analysis of progression free survival and overall survival.
Table 3.
Multivariate analysis of progression free survival and overall survival.
Fig 4.
Kaplan-Meier plots of cohort of 211 patients treated with 1st line EGFR TKI; (a) PFS by brain metastasis in ECOG 0–1 patients, (b) PFS by brain metastasis in ECOG 2–4 patients, (c) OS by brain metastasis in ECOG 0–1 patients, and (d) OS by brain metastasis in ECOG 2–4 patients.
Table 4.
Multivariate analysis of progression free survival and overall survival in males only.
Table 5.
Multivariate analysis of progression free survival and overall survival in female never-smokers aged ≤ 65 with ECOG PS 0–1 at diagnosis.
Table 6.
Hazards for survival from univariate analysis of populations with smoking characteristics as indicated across 3 studies do not show any significant differences in survival outcomes, while those from a more recent Korean study show that smoking has a significant impact, especially smoking dosage greater than 30 pack years.